Groundbreaking research suggests that the shingles vaccine could significantly reduce the risk of cardiovascular events. According to the first global systematic review and meta-analysis on the subject, adults who received the jab had an 18% lower risk of heart attack or stroke, with the effect also observed in younger adults aged 18 and above.
Traditionally recommended for older or immunosuppressed individuals, the vaccine may offer broader benefits by reducing inflammation linked to shingles, a known contributor to cardiovascular disease. The findings, based on 19 studies including both observational data and clinical trials, will be presented at the European Society of Cardiology congress in Madrid.
Experts stress that while the results are promising, further research is needed to confirm whether the protective effect is directly caused by vaccination. Still, the study adds to growing evidence that vaccines can provide protection beyond infection control, potentially serving as a preventive tool against cardiovascular disease.
